Mepsevii
Named-patient access overview. Mepsevii is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Mepsevii (vestronidase alfa) is a recombinant human beta-glucuronidase enzyme replacement therapy approved by the US Food and Drug Administration in November 2017 for mucopolysaccharidosis type VII (MPS VII, also known as Sly syndrome), an ultra-rare lysosomal storage disorder. The product is marketed approximately by Ultragenyx Pharmaceutical. Mepsevii is delivered by intravenous infusion every two weeks at a recommended dose of 4 mg per kg.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Mepsevii
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Mepsevii is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Mepsevii in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Mepsevii
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.